TSE Systems

The gap between preclinical findings and clinical outcomes remains one of the most significant challenges in drug development. At TSE Systems, we have observed that this translational barrier often stems from incomplete behavioral characterization during early-stage research. Our latest PhenoWorld platform addresses this by enabling multi-parameter assessment within a single experimental protocol - simultaneously capturing metabolic function, activity, cognition, feeding and social behavior with research-grade precision. The result? More robust data sets that support stronger translational predictions, ultimately accelerating your pathway from target validation to clinical candidates. Key advantages for your research program: - Reduced animal numbers through comprehensive single-cohort analysis in group-housed conditions - Enhanced reproducibility via automated, bias-free data acquisition - Seamless integration with your existing experimental workflows Interested in discussing how integrated phenotyping could strengthen your preclinical pipeline? Let's connect.

Behind every breakthrough that changed a life - quietly, without recognition - were animals. Today, we remember that. Alternatives are advancing - organoids, NAMs, organ-on-chip - and we support that progress. But the biology of a living organism remains irreplaceable for understanding how complex systems interact. We are not there yet, and pretending otherwise slows the science that saves lives. Responsible research means never using an animal when an alternative exists, designing studies with the fewest animals possible, and ensuring every animal lives as well as science allows - because stressed animals don't just suffer; they produce unreliable data. This is what the 3Rs were always meant to be: not a box to tick, but a scientific standard. At TSE Systems, we build tools that make Refinement measurable: group housing that supports natural behavior, automated monitoring that removes observer stress, environments designed around the animal. They did not choose to contribute. That is precisely why we owe them something in return: the commitment that their role is never taken lightly, never wasted, and always met with the highest standards of care. Better welfare is not just a guideline. It is better science.

We are excited to share that we will participate in BonnBrain 2026 – From Genes to Circuits and Behavior, taking place March 23–25, 2026 at the DZNE in Bonn. The conference brings together leading researchers from around the world to discuss how neural circuits shape behavior, with keynote lectures, symposia, poster sessions, and networking across disciplines. Looking forward to engaging discussions and connecting with the neuroscience community.

A new study from Prof. Dr. Urs Meyer and colleagues at the University of Zurich, published in Neuropsychopharmacology, investigates how maternal immune activation (MIA) during pregnancy affects neurodevelopment in offspring. The researchers found that 40–50% of male mice exposed to prenatal immune activation developed locomotor hyperactivity during adolescence, followed later by impulsivity and deficits in pre-attentive filtering, features associated with ADHD-like phenotypes. To study reward processing and impulsivity, the team used the IntelliCage system, a fully automated behavioral platform that enables cognitive testing directly in the home cage of group-housed mice. Using IntelliCage, the researchers assessed: • Reward preference • Incentive motivation • Delay-of-reinforcement impulsivity This approach allows longitudinal behavioral phenotyping with minimal experimenter interference, providing a more naturalistic view of complex behavioral traits. The study also identified age-dependent alterations in dopamine and norepinephrine systems in cortical and subcortical brain regions that correlated with the observed behavioral changes. Importantly, treatment with methylphenidate (MPH) – a first-line ADHD medication – normalized both hyperactivity and abnormal neuronal activation patterns in susceptible animals, supporting the translational relevance of this model. Together, these findings highlight how prenatal immune challenges can contribute to ADHD-related neurobiology in susceptible individuals, and how automated behavioral systems help uncover these complex mechanisms.

A hidden regulator of energy metabolism in adipocytes. A new study from Prof. Christian Wolfrum’s lab, published in Molecular Cell (2026), identifies MEDAG as a previously unrecognized regulator of metabolic activity in adipose tissue. The team discovered that MEDAG functions as an A-kinase anchoring protein (AKAP) that directly interacts with the regulatory subunit PKA-RIIβ, helping organize and fine-tune intracellular PKA signaling. Why is this important? MEDAG appears to act as a molecular brake on energy expenditure in adipocytes. When researchers generated adipocyte-specific Medag knockout mice, the metabolic phenotype shifted dramatically: • Energy expenditure increased • Animals were protected from diet-induced obesity • Metabolism shifted toward greater fatty-acid oxidation Importantly, these changes occurred without differences in food intake or physical activity. Using indirect calorimetry with the TSE Systems PhenoMaster, the researchers demonstrated that loss of MEDAG significantly elevates metabolic rate and alters substrate utilization. Mechanistically, the study uncovers a fascinating regulatory loop: MEDAG binds PKA-RIIβ, stabilizing PKA signaling complexes. When PKA becomes activated, it phosphorylates MEDAG, which then helps prevent excessive PKA activity. Without MEDAG, this restraint disappears – leading to enhanced PKA signaling and increased energy dissipation in adipose tissue. These findings position MEDAG as a new regulator of adipocyte metabolism and a potential target for metabolic disease research.

We are hiring: Territory Manager – Northeast (Life Sciences), USA, full-time. Join TSE Systems Inc. and help advance biomedical research! We are looking for a dynamic sales professional to grow relationships with academic, biotech, and pharma labs in the Northeast U.S. & Eastern Canada. Apply now: eu1.hubs.ly/H0srP_s0

What distinguishes us in the preclinical instrumentation market isn't just our technology - it is our understanding of how that technology gets used. Many of us at TSE Systems come from scinetific backgrounds - we have personally wrestled with experimental design challenges, troubleshot equipment mid-protocol, and felt the pressure of tight publication deadlines. This perspective shapes everything: product development prioritizes actual research workflows, not theoretical use cases. Support teams anticipate questions before they are asked. Training programs address practical implementation, not just operational basics. We built TSE Systems on a simple principle: create the tools we wished we would had in the lab. Three decades later, serving researchers across 50+ countries, that principle still guides us. Because advancing science requires more than sophisticated equipment—it requires partners who genuinely understand the work.

We are excited to welcome the Alabama R&D Tissue Slicer to the TSE Systems portfolio - a technology widely recognized by researchers as a gold standard for preparing high-quality precision tissue slices. For decades, this platform has supported ex vivo research across physiology, pharmacology, toxicology, and translational science, enabling reproducible preparation of viable tissue with exceptional structural integrity and consistency. By becoming the exclusive global distributor, TSE Systems expands its commitment to providing scientists with best-in-class technologies that strengthen experimental rigor - from in vivo phenotyping to ex vivo tissue analysis. We are proud to partner with Alabama R&D to make this established technology more accessible to the global research community and to support scientists in advancing discovery with reliable, high-quality tools. If you are exploring precision tissue slicing for your research workflows, we would be glad to connect. Find our more: eu1.hubs.ly/H0s75Wt0 #Partnership #LifeScience #ResearchTools #TSESystems

Metabolic phenotyping generates complex datasets. Getting to meaningful insights should feel simpler. PhenoMaster Analytics brings data analysis back into the system - helping researchers work with large, multi-parameter datasets without unnecessary steps or external tools. From streamlined data handling issue of multiple cohort runs, integrated powerfull statistical workflows (including ANOVA/ANCOVA, correlation/regression, PCA and tSNE analysis) to data visualisation. This is just a glimpse of what is possible. If you would like to explore how PhenoMaster Analytics can support your research - we would be happy to walk you through it.

What an inspiring day at the PhenoMaster User Workshop 2026! Huge thanks to Prof. Erik A. Richter for hosting us at the @University of Copenhagen and to all our brilliant speakers Jan-Wilhelm Kornfeld and Casper Møller Sigvardsen. Your insights made this a true hub for exchange and collaboration. We loved sharing our new CaloMax HS live and seeing researchers explore innovative ways to make experiments smarter and faster. Workshops like this fuel ideas, connections, and breakthroughs in rodents phenotyping. We are excited to bring future workshops to new regions and look forward to connecting with researchers across the globe. #PhenoMaster #CaloMaxHS #Innovation #Collaboration #TSESystems

Our production team is growing! We are looking for a motivated Electromechanical/Electronics Technician (m/f/d/x) to join us in Berlin. If you enjoy working in a hands-on, high-quality manufacturing environment and want to help create innovative solutions that advance scientific research worldwide, we want to hear from you. Take the next step in your career and apply today: job@tse-systems.com More info: eu1.hubs.ly/H0rRthz0 #Hiring #Elektroniker #SMT #SMD #BerlinJobs #Careers#LifeScience

Wishing our customers, partners and colleagues a joyful start to the Lunar New Year! May the Year of the Horse bring strength, success, and new opportunities. Thank you for your trust and partnership. Here’s to another great year together.

Happy Valentine's Day from TSE Systems! Whether you're studying pair bonding in voles, social preference in mice, or maternal behavior in rats—we're here to help you measure what matters. Here is to love, science, and reproducible results. 💙 P.S. Fun fact: Male mice who sing better ultrasonic courtship songs are preferred by females. Even in rodents, it's all about the performance. 🎤🐭

Mach den Unterschied – werde Teil von TSE Systems! Wir sind ein globales, mittelständisches Unternehmen mit über 130 Jahren Erfahrung und treiben die wissenschaftliche Forschung weltweit voran. Aktuell suchen wir eine:n Controller (m/w/d/x) Vollzeit in Berlin, der/die unser Finanzteam verstärkt und ein zentraler Partner für Management und Fachbereiche wird. Wir bieten: Attraktive Vergütung & Bezahlung nach Stunden Flache Hierarchien & kollaborative Kultur Flexible Arbeitszeiten Lernen & Entwicklung Eine verantwortungsvolle und abwechslungsreiche Tätigkeit in einem erfolgreichen Unternehmen des Sondermaschinenbaus im Gesundheitssektor Du bringst mit: Studium BWL/WiWi/WING oder vergleichbare kaufmännische Ausbildung (Controlling/Finanzen/Rechnungswesen) Starke Zahlenaffinität & analytisches Denkvermögen Kommunikationsstark als Schnittstelle zwischen den Fachbereichen Digitale Kompetenz (z.B. FP+A) & sehr gute Excel-Kenntnisse Selbstständige, strukturierte Arbeitsweise & Hands-on-Mentalität Sehr gute Deutsch (mind. C1)- & gute Englischkenntnisse (mind. B2) Haben wir Dein Interesse geweckt? Dann freuen wir uns auf Deine vollständigen und aussagekräftigen Bewerbungsunterlagen per E-Mail an job@TSE-Systems.com. Weitere Infos: eu1.hubs.ly/H0rGLXp0 #Controller #Controlling #FinanceJobs #BerlinJobs #JobsBerlin #Karriere #Hiring

"Rethinking Metabolic Dysfunction in Alzheimer's Disease: When ""Preservation"" Isn't Protective. The prevailing narrative in Alzheimer's research frames metabolic dysfunction as hypometabolism - reduced glucose uptake, mitochondrial failure, and energy deficit. A new study in Nature challenges this assumption with provocative findings: tau pathology doesn't impair whole-body metabolism. It preserves it. Using TSE Systems' PhenoMaster, researchers demonstrated that tau mice maintain glucose tolerance, sustain metabolic rhythms, and preferentially utilize carbohydrates - all features that decline during normal aging. Yet this metabolic ""preservation"" isn't beneficial. The paradox: Enhanced glucose availability fuels cortical hyperexcitability by supporting excessive glutamate biosynthesis. The brain becomes metabolically inflexible - locked into carbohydrate utilization and unable to adapt fuel use to match neuronal demand. Sleep architecture deteriorates. Network synchrony degrades. Cognitive function declines. This reframes a fundamental question: Is Alzheimer's a disease of metabolic insufficiency or metabolic rigidity? Implications for therapeutic development: If the issue is inflexibility rather than failure, interventions should target metabolic adaptability - restoring the brain's capacity to dynamically match fuel supply to neuronal activity, excitation, and sleep/wake states. This work exemplifies how multi-modal phenotyping reveals mechanisms invisible to single-endpoint assays. By simultaneously capturing energy expenditure, fuel utilization, activity patterns, and circadian dynamics across disease progression, the researchers identified a metabolic signature of early tauopathy that preceded cognitive decline. The translational implications are significant: if hyperphosphorylated tau alters metabolism before tangles form, metabolic biomarkers could identify therapeutic windows earlier than current approaches allow.Congratulations to Dr. Shannon Macauley and the entire research team on this paradigm-shifting contribution to understanding Alzheimer's pathogenesis. Read the full paper: eu1.hubs.ly/H0ry3PS0

Obesity research has largely focused on metabolic parameters - but what about the brain? Obesity is associated with cognitive impairment, altered reward processing, anxiety-like behaviors, and disrupted circadian activity patterns. Comprehensive phenotyping of obesity models (DIO, ob/ob, db/db, MC4R knockouts) requires both metabolic and neurobehavioral assessment to: - Evaluate CNS complications of metabolic disease - Assess cognitive side effects of anti-obesity therapeutics - Understand gene-behavior interactions in polygenic obesity - Model human obesity-related cognitive decline - Automated Behavioral Testing in Group-Housed Obese Mice TSE Systems' IntelliCage enables automated behavioral and cognitive phenotyping in socially-housed mice -eliminating social isolation stress, enabling circadian profiling, and reducing handling effects. For obesity research, we've developed IntelliCage with Fat Mouse Corners - specifically engineered to accommodate obese mice up to 60–70g body weight. Key Capabilities: ✓ Automated 24/7 monitoring in group-housed conditions (up to 16 mice) ✓ Cognitive testing: place learning, reversal tasks, extinction, reward processing ✓ Continuous behavioral tracking across disease progression or intervention ✓ Circadian behavioral profiling without investigator intervention ✓ Compatible with DIO and genetic obesity models IntelliCage with Fat Mouse Corners enables rigorous, automated behavioral phenotyping in obesity models under natural social conditions - providing comprehensive data beyond metabolic parameters alone. Studying obesity models? Let's discuss how IntelliCage can enhance your behavioral phenotyping. Contact us to know more: eu1.hubs.ly/H0rwmSS0

We will be attending the Ingestive Behavior Conference in St. Moritz from February 8–12! Our Product Manager Dr. Pierre-Louis Ruffault, will give a talk titled: “Automated and combinatorial studies of metabolic, behavioral, and physiological aspects: a new approach toward improving translational studies in rodents.” The presentation will highlight how integrated and automated approaches can advance translational research in preclinical models. If you will be there, let’s connect and exchange ideas. Looking forward to great discussions in St. Moritz! #IngestiveBehavior #MetabolicResearch #PreclinicalResearch #TSESystems #PhenoMaster

Scientists at Rockerfeller University, powered by PhenoMaster NG metabolic platform, have identified a game-changing neural pathway that could revolutionize how we treat obesity by targeting energy burning instead of hunger. The Breakthrough: Researchers discovered specific brain neurons in the dorsal raphe nucleus that act like a "metabolic switch." When these neurons are turned off, mice stay lean even on high-fat diets, without affecting their appetite. The Target GPR6: The team pinpointed GPR6, a member of the G-coupled receptor Class A metabotropic receptor, as the molecular switch on these neurons. Blocking GPR6 supercharges brown fat to burn more calories, offering a completely new approach to weight management. Why This Matters: With nearly 40% of people worldwide affected by obesity, current treatments focus on suppressing appetite, often with side effects and poor long-term results. This discovery opens the door to safer, more effective therapies that work by boosting your body's natural calorie-burning furnace instead of fighting hunger. Published in @Nature Communications, this research represents a fundamental shift from "eat less" to "burn more" - potentially the future of obesity medicine.

Obesity drug discovery no longer works with single-target thinking. The shift toward dual and triple agonists has made one thing clear: understanding metabolism requires continuous, high-resolution in vivo phenotyping, not snapshot measurements. In our latest case study, “Polyagonist Therapies in Obesity», we summarize how research groups used the PhenoMaster platform to capture energy expenditure, substrate utilization, feeding behavior and body-weight changes across the full circadian cycle. Based entirely on peer-reviewed publications, the case study shows how continuous metabolic data supported mechanistic understanding and translational development of next-generation polyagonist therapies – from early preclinical insights to clinically relevant outcomes. 👉 Read the full case study here: eu1.hubs.ly/H0rgWBJ0